If you would like to explore the possibility of participating in a clinical trial at Guthrie, please call 1-800-836-0388.

As a Guthrie cancer patient you will have the unique opportunity to participate in one or more of some 100 clinical research trials that involve new treatments for many cancer types.

As a Guthrie patient you may have the unique opportunity to take part in clinical research trials for atrial fibrillation, congestive heart failure, lipid disorders, heart attack and many more cardiology disease states.

As a Guthrie patient you may have an opportunity to take part in clinical research trials for celiac disease, Crohn’s disease, ulcerative colitis, reflux disease, hepatitis and many more gastroenterology disease states.

Clinical trials study new ways to prevent, detect and treat disease. If you take part in research, you help advance new investigational medical therapies. 

Title: A descriptive and comparative analysis of frailty in rural versus urban cancer patients undergoing major surgical oncologic procedures
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator:

Macfie MD, Rebekah

Sponsors: Internal
Details (Identifier #): NCT05694338
Title: A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
Department: Cardiology
Diagnosis: Cardiac - Hyperlipidemia
Principal Investigator:

Sharma MD, Saurabh

Sponsors: Merck Sharp & Dohme LLC
Details (Identifier #): pending
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index ?27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
Department: Endocrinology
Diagnosis: Endocrine - Growth Hormone
Principal Investigator:

Yavuz MD, Sahzene

Sponsors: Eli Lilly And Company
Title: A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of MEDI3506 in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (OBERON)
Department: Pulmonary
Diagnosis: Lung - COPD
Principal Investigator:

Hehn MD, Boyd

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): 05166889
Title: A Prospective, Multi-Center, Non-Randomized, SinGle-Arm Study of the BDTM Low ProfILe Vascular Covered Stent in PerIpheral ArTerY Disease (AGILITY)
Department: Vascular Surgery
Diagnosis: Vascular
Principal Investigator:

Marica M.D., Silviu

Sponsors: Becton, Dickinson and Company
Details (Identifier #): NCT06111469
Title: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator:

Poulose MD, Joyson

Sponsors: ECOG-ACRIN Cancer Research Group
Details (Identifier #): NCT06096844
Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF VE303 FOR PREVENTION OF RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION:
THE RESTORATIVE303 STUDY
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator:

Srivatana MD, Ukorn

Sponsors: Vedanta Biosciences, Inc.
Details (Identifier #): NCT06237452
Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Department: Oncology
Diagnosis: Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Gilead Sciences
Details (Identifier #): NCT05633654
Title: A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of
Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus
Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) – LIVIGNO-4
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator:

Poulose MD, Joyson

Sponsors: AbbVie
Details (Identifier #): NCT06236438
Title: A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator:

Kasireddy MD, Vineela

Sponsors: ALLIANCE
Details (Identifier #): NCT04457596
Showing 1-10 of 40 Results